Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease

Experimental and Molecular Medicine

Volumn 46, Issue 2, 2014, Pages

  Choi, Bo Ryoung ^a   Cho, Woo Hyun ^a   Kim, Jiyoung ^b   Lee, Hyong Joo ^b   Chung, Chihye ^a   Jeon, Won Kyung ^c   Han, Jung Soo ^a  

^a Konkuk University   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Alzheimer's disease; Astrocyte; Cortex; Hippocampus; Mice; Receptor for advanced glycation end products (RAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADULT; AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HIPPOCAMPAL CA1 REGION; IMMUNOREACTIVITY; MOUSE; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; ANIMAL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; CA1 REGION, HIPPOCAMPAL; HUMANS; MICE; MICE, TRANSGENIC; NEURONS; RECEPTORS, IMMUNOLOGIC; TAU PROTEINS;

EID: 84896884534     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.147     Document Type: Article

References (30)

1. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physioll Rev 2001; 81: 741-766.
3. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45: 675-688.
4. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
5. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003; 24: 1063-1070.
6. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084-6089.
7. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45(Suppl 3), S77-S80.
8. Yan SD, Chen X, Fu J, ChenM, ZhuH, Roher A et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691.
9. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 2012; 33: 1400-1410.
10. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994; 91: 7787-7791.
11. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
12. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001; 888: 256-262.
13. Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 2008; 1230: 273-280.
14. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004; 23: 4096-4105.
15. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 2009; 23: 2639-2649.
16. LaFerla FM, Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 2005; 11: 170-176.
17. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421.
18. Leclerc E, Sturchler E, Vetter SW, Heizmann CW. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease. Rev Neurosci 2009; 20: 95-110.
19. Bialowas-McGoey LA, Lesicka A, Whitaker-Azmitia PM. Vitamin E increases S100B-mediated microglial activation in an S100B-overexpressing mouse model of pathological aging. Glia 2008; 56: 1780-1790.
20. Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE et al. Amyloid deposition and influx transporter expression at the bloodbrain barrier increase in normal aging. J Neuropathol Exp Neurol 2010; 69: 98-108.
21. Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD Miller MC et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006; 112: 405-415.
22. Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011; 31: 91-97.
23. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19: 939-945.
24. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E et al. RAGE mediates amyloid-beta peptide transport across the bloodbrain barrier and accumulation in brain. Nat Med 2003; 9: 907-913.
25. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 2008; 28: 3521-3530.
26. Takuma K, Fang F, Zhang W, Yan S, Fukuzaki E, Du H et al. RAGEmediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci USA 2009; 106: 20021-20026.
27. Duff K, Suleman F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct Genomic Proteomic 2004; 3: 47-59.
28. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 4766-4770.
29. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 2010; 24: 1043-1055.
30. Origlia N, Bonadonna C, Rosellini A, Leznik E, Arancio O, Yan SS et al. Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. J Neurosci 2010; 30: 11414-11425.